• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Metabolon Adding New Data to Platform to Improve Biomarker Discovery

News
Article

The company will offer clients access to spectral data files.

Stock.adobe.com

Adobe.stock.com

Metabolon Inc. announced that it is adding spectral data files to its offerings for the Global Discovery Panel. This move is just the latest addition to the company’s precision medicine applications.

Spectral data is gathered during a mass spectrometry (MS)-based metabolomic analysis and contains information about the metabolites present in the structure. Clients should be able to use this data to discovery new biomarkers.

In a press release, Metabolon CEO Ro Hastie said, “The availability of spectral data enhancement not only provides clients with a more comprehensive view of their metabolomics data but also reinforces our commitment to transparency and delivering unparalleled value to our clients.”

In May of this year, Metabolon announced that it had closed on a $60 million credit facility, which it planned to use to enhance the research available on its platform.2

In a press release issued at the time, Hastie said, “We are extremely pleased to announce this successful financing, marking a significant milestone for Metabolon. This infusion of additional capital and robust process leading up to it underscore the strong investor confidence in Metabolon's vision, capabilities, and market potential within the multiomics and metabolomics industry. As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space."

In the same press release, the company’s chief financial officer Gerry Haines said, “Despite relatively challenging capital markets environment, this investment of non-dilutive growth capital, combined with the equity round before it, are proof that top-performing companies like Metabolon continue to attract funding. We are thrilled to have this top-tier investor backing us, enabling us to advance scientific research, drive breakthrough discoveries, and further develop our technology as we bring market-leading metabolomics and bioinformatics solutions to the multiomics community.”

Rob Lake, senior managing director at Life Sciences at Trinity, added, “We are excited to partner with Metabolon, a company that has demonstrated innovation and excellence in the life sciences sector. By leveraging their cutting-edge technology and extensive experience, the team has the potential to accelerate research and we look forward to supporting the company's ongoing growth and expansion in the industry."

In March, Metabolon announced a partnership with Cardiff University Centre for Neuropsychiatric Genetics and Genomics.3 The two companies stated that the partnership would focus on developing new drugs targets.

In a press release issued at the time, Cardiff University clinical reader Dr. Emma Tallantyre said, “Predictive biomarkers are needed to inform more personalized care for people with multiple sclerosis. This collaboration will provide detailed metabolomic profiles on a large, longitudinal cohort for whom we already have other multi-dimensional data. This represents an exciting opportunity to improve predictive models and thereby aim for more accurate predictions of outcome for people with MS.”

In the same press release, Metabolon chief business officer Dr. Karl Bradshaw said, “Currently, there is no cure for MS, only disease-modifying therapies that can slow disease progression. By leveraging Cardiff's extensive research and our decades of expertise in generating the highest quality and most accurate metabolomics data on the market, we aim to redefine our understanding of multiple sclerosis to make a profound impact on the lives of those affected by this devastating disease."

Sources

  1. Metabolon Now Includes Spectral Data Files for All Global Discovery Panel Projects. Metabolon Inc. May 28, 2024. https://www.prnewswire.com/news-releases/metabolon-now-includes-spectral-data-files-for-all-global-discovery-panel-projects-302156724.html
  2. Metabolon Secures $60 Million Credit Facility to Drive Growth and Innovation. Metabolon. May 16, 2024. Accessed May 28, 2024. https://www.prnewswire.com/news-releases/metabolon-secures-60-million-credit-facility-to-drive-growth-and-innovation-302146722.html
  3. Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research. Metabolon, Inc. March 12, 2024. Accessed May 28, 2024. https://www.prnewswire.com/news-releases/metabolon-and-cardiff-university-centre-for-neuropsychiatric-genetics-and-genomics-forge-alliance-to-propel-multiple-sclerosis-research-302085708.html
Related Videos
Related Content